Taking stock of the drug industry, from the lab to the medicine chestJanuary 27, 2023Check out STAT+Sponsored ByBy Ed SilvermanPharmalot Columnist, Senior Writer Aram Boghosian for STAT STAT+ | A bellwether for biosimilars: Why the new competition for Humira matters to pharma, payers, and patients The first biosimilars for Humira are about to hit the market. Here's why that matters for drugmakers, payers, and patients. By Ed Silverman STAT+ | Legend says its CAR-T outperformed conventional therapy for multiple myeloma The data from Legend add to a broader push by drugmakers to move cellular therapies into earlier lines of care. By Jason Mast STAT+ | After bullying allegations, Eric Lander will return to run a lab at the Broad Institute The Broad's director said Lander is "committed to upholding" the genomics research center's "inclusive culture of respect." By Megan Molteni Nicholas Florko/STAT It's easy to buy flavored vapes in California, even in cities with longtime bans California cities are supposed to be cracking down on sales of flavored vapes, which are now illegal across the state. By Nicholas Florko STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions, and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments